Complement factor H increases risk for atrophic age-related macular degeneration.

OBJECTIVE To determine if the complement factor H gene (CFH) determines risk for development of geographic atrophy (GA). DESIGN Retrospective case-control study. PARTICIPANTS AND CONTROLS The independent case-control data set contained 647 age-related macular degeneration (AMD) cases (grades 3, 4, or 5) and 163 controls (grades 1 or 2). METHODS To determine if CFH had any effect on determining risk for development of GA in an independent case-control data set of 647 AMD cases and 163 controls, the rs1061170 single-nucleotide polymorphism was tested for association, separating grades and analyzing them independently against the controls. Odds ratios were calculated using standard logistic regression models. MAIN OUTCOME MEASURES The outcome variable was AMD affection status, and genotypes were coded according to a log-additive model. RESULTS There were 407 grade 5, 107 grade 4, 133 grade 3, 35 grade 2, and 128 grade 1 individuals. There was significant association with AMD when comparing grades 3, 4, and 5 versus the controls. The highest odds ratio was obtained when analyzing the grade-4 cases versus the grade-1 controls (OR = 3.217, P<0.0001). CONCLUSIONS Our results indicate that CFH increases the risk of developing GA (grade 4) as well as neovascular (grade 5) and milder (grade 3) disease. Although neovascular disease is responsible for the majority of severe vision loss with AMD, GA is also a significant cause of vision loss, and without effective treatment. Therefore, an attempt to clarify its pathogenesis is of the utmost importance.

[1]  M. Tso,et al.  Antiretinal antibodies in serum of patients with age-related macular degeneration. , 1991, Ophthalmology.

[2]  S. Russell,et al.  Drusen associated with aging and age‐related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  M. Killingsworth,et al.  Macrophages related to Bruch's membrane in age-related macular degeneration , 1990, Eye.

[4]  Johanna M Seddon,et al.  Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. , 2003, Ophthalmology.

[5]  R. T. Smith,et al.  A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Edwards,et al.  Complement Factor H Polymorphism and Age-Related Macular Degeneration , 2005, Science.

[7]  S. Fisher,et al.  Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk , 2005 .

[8]  George A. Williams,et al.  The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. , 1999, Controlled clinical trials.

[9]  M. Cahill,et al.  Recurrence of retinal pigment epithelial changes after macular translocation with 360 degrees peripheral retinectomy for geographic atrophy. , 2005, Archives of ophthalmology.

[10]  R. Klein,et al.  Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. , 2003, Ophthalmology.

[11]  J. Gilbert,et al.  Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. , 2006, Investigative ophthalmology & visual science.

[12]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[13]  B. Hammond,et al.  The age-related eye disease study (AREDS). , 2002, Nutrition reviews.

[14]  J. Gilbert,et al.  Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration , 2005, Science.

[15]  J. Haines,et al.  Phenotypic heterogeneity in families with age-related macular degeneration. , 1996, American journal of ophthalmology.

[16]  G. Jensen,et al.  14-year incidence, progression, and visual morbidity of age-related maculopathy: the Copenhagen City Eye Study. , 2005, Ophthalmology.

[17]  P. Mitchell,et al.  Systemic use of anti-inflammatory medications and age-related maculopathy: the Blue Mountains Eye Study , 2003, Ophthalmic epidemiology.

[18]  Association Between C-Reactive Protein and Age-Related Macular Degeneration , 2004 .

[19]  J. Gilbert,et al.  Comparing age-related macular degeneration phenotype in probands from singleton and multiplex families. , 2005, American journal of ophthalmology.

[20]  A. Schachat New treatments for age-related macular degeneration. , 2005, Ophthalmology.

[21]  R. Klein,et al.  Systemic markers of inflammation, endothelial dysfunction, and age-related maculopathy. , 2005, American journal of ophthalmology.

[22]  Gui-Shuang Ying,et al.  The role of apoptosis in age-related macular degeneration. , 2002, Archives of ophthalmology.